All ABPI members and any pharmaceutical company that follows ABPI's Code of Practice for the Pharmaceutical Industry are required to disclose certain transfers of value - payments and other benefits in kind made to healthcare organisations that they work with.
The disclosure of certain payments and benefits in kind is about bringing further transparency to the relationship between the pharmaceutical industry and the healthcare professionals and organisations it works with. It is a relationship that is critical to the future of medical innovation and patient care and as such, should meet the high expectations of patient and wider stakeholders.
In its guidance Managing conflicts of interest in the NHS, NHS England recommends that NHS organisations should 'seek to ensure that staff who are subject to wider transparency initiatives such as the ABPI Disclosure UK scheme are aware of and comply with them'.
The Academy of Medical Royal Colleges (AoMRC) also advocates HCPs and ORDMs 'voluntarily comply' with publication on Disclosure UK in its statement Disclosure of payments to healthcare professionals.
In the UK, consent is not required from healthcare organisations in order to disclose transfers of value made to them.